Studies of inhibitor binding to the [4Fe-4S] cluster of quinolinate synthase. 2012

Alice Chan, and Martin Clémancey, and Jean-Marie Mouesca, and Patricia Amara, and Olivier Hamelin, and Jean-Marc Latour, and Sandrine Ollagnier de Choudens
Laboratoire de Chimie de Biologie des Métaux, UMR 5249, Université Joseph Fourier, Grenoble-1, CNRS-CEA 17, Rue des Martyrs, 38054 Grenoble Cedex 9, France.

Stop for NadA! A [4Fe-4S] enzyme, NadA, catalyzes the formation of quinolinic acid in de novo nicotinamide adenine dinucleotide (NAD) biosynthesis. A structural analogue of an intermediate, 4,5-dithiohydroxyphthalic acid (DTHPA), has an in vivo NAD biosynthesis inhibiting activity in E. coli. The inhibitory effect can be explained by the coordination of DTHPA thiolate groups to a unique Fe site of the NadA [4Fe-4S] cluster.

UI MeSH Term Description Entries
D007506 Iron-Sulfur Proteins A group of proteins possessing only the iron-sulfur complex as the prosthetic group. These proteins participate in all major pathways of electron transport: photosynthesis, respiration, hydroxylation and bacterial hydrogen and nitrogen fixation. Iron-Sulfur Protein,Iron Sulfur Proteins,Iron Sulfur Protein,Protein, Iron-Sulfur,Proteins, Iron Sulfur,Proteins, Iron-Sulfur,Sulfur Proteins, Iron
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D004099 Dihydroxyacetone Phosphate An important intermediate in lipid biosynthesis and in glycolysis. Dihydroxyacetone 3-Phosphate,3-Phosphate, Dihydroxyacetone,Dihydroxyacetone 3 Phosphate,Phosphate, Dihydroxyacetone
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D019883 Alkyl and Aryl Transferases A somewhat heterogeneous class of enzymes that catalyze the transfer of alkyl or related groups (excluding methyl groups). EC 2.5. Alkyltransferase,Alkyltransferases,Aryltransferase,Aryltransferases
D029968 Escherichia coli Proteins Proteins obtained from ESCHERICHIA COLI. E coli Proteins

Related Publications

Alice Chan, and Martin Clémancey, and Jean-Marie Mouesca, and Patricia Amara, and Olivier Hamelin, and Jean-Marc Latour, and Sandrine Ollagnier de Choudens
August 2008, FEBS letters,
Alice Chan, and Martin Clémancey, and Jean-Marie Mouesca, and Patricia Amara, and Olivier Hamelin, and Jean-Marc Latour, and Sandrine Ollagnier de Choudens
March 2019, Chemical communications (Cambridge, England),
Alice Chan, and Martin Clémancey, and Jean-Marie Mouesca, and Patricia Amara, and Olivier Hamelin, and Jean-Marc Latour, and Sandrine Ollagnier de Choudens
May 2005, Journal of the American Chemical Society,
Alice Chan, and Martin Clémancey, and Jean-Marie Mouesca, and Patricia Amara, and Olivier Hamelin, and Jean-Marc Latour, and Sandrine Ollagnier de Choudens
September 1997, Biochemistry,
Alice Chan, and Martin Clémancey, and Jean-Marie Mouesca, and Patricia Amara, and Olivier Hamelin, and Jean-Marc Latour, and Sandrine Ollagnier de Choudens
July 2004, Journal of the American Chemical Society,
Alice Chan, and Martin Clémancey, and Jean-Marie Mouesca, and Patricia Amara, and Olivier Hamelin, and Jean-Marc Latour, and Sandrine Ollagnier de Choudens
March 2022, Journal of inorganic biochemistry,
Alice Chan, and Martin Clémancey, and Jean-Marie Mouesca, and Patricia Amara, and Olivier Hamelin, and Jean-Marc Latour, and Sandrine Ollagnier de Choudens
April 2022, Journal of the American Chemical Society,
Alice Chan, and Martin Clémancey, and Jean-Marie Mouesca, and Patricia Amara, and Olivier Hamelin, and Jean-Marc Latour, and Sandrine Ollagnier de Choudens
November 2002, Journal of the American Chemical Society,
Alice Chan, and Martin Clémancey, and Jean-Marie Mouesca, and Patricia Amara, and Olivier Hamelin, and Jean-Marc Latour, and Sandrine Ollagnier de Choudens
December 2011, Angewandte Chemie (International ed. in English),
Alice Chan, and Martin Clémancey, and Jean-Marie Mouesca, and Patricia Amara, and Olivier Hamelin, and Jean-Marc Latour, and Sandrine Ollagnier de Choudens
May 2023, Protein science : a publication of the Protein Society,
Copied contents to your clipboard!